Holen Sie sich die Stockscreener-App
18.71
0.92%
0.17
Vorhandelsmarkt:
18.40
-0.31
-1.66%
Schlusskurs vom Vortag:
$18.54
Offen:
$18.75
24-Stunden-Volumen:
457.81K
Relative Volume:
1.44
Marktkapitalisierung:
$1.35B
Einnahmen:
$384.10M
Nettoeinkommen (Verlust:
$-9.07M
KGV:
-133.64
EPS:
-0.14
Netto-Cashflow:
$11.10M
1W Leistung:
+2.02%
1M Leistung:
-9.13%
6M Leistung:
-11.87%
1J Leistung:
-0.90%
1-Tages-Spanne:
$18.49
$18.93
1-Wochen-Bereich:
$18.27
$19.05
52-Wochen-Spanne:
$16.56
$28.15
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Firmenname
Kiniksa Pharmaceuticals International Plc
Sektor
Telefon
(781) 431-9100
Adresse
23 OLD BOND STREET, FLOOR 3, LONDON
Vergleichen Sie KNSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
18.71 | 1.35B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2024-05-03 | Eingeleitet | Wells Fargo | Overweight |
| 2020-06-29 | Bestätigt | BofA Securities | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-12-12 | Bestätigt | Wedbush | Outperform |
| 2018-06-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Kiniksa Pharmaceuticals International Plc Aktie (KNSA) Neueste Nachrichten
Kiniksa Pharmaceuticals Reports Strong 2024 Financial Results and Provides 2025 Revenue Guidance - Defense World
Kiniksa Pharmaceuticals COO Tessari Eben sells shares worth $255,413 - Investing.com
Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight - GlobeNewswire Inc.
Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance - The Manila Times
Kiniksa Pharmaceuticals Reports Preliminary 2024 Net - GlobeNewswire
Kiniksa's ARCALYST Soars 79% to $416M in 2024, Projects Strong 2025 Growth to $580M - StockTitan
Kiniksa Pharmaceuticals to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Kiniksa Pharmaceuticals COO Tessari Eben sells shares worth $470k - Investing.com
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Acquired by Fmr LLC - Defense World
Kiniksa Pharmaceuticals CFO sells shares worth $593,997 By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals CFO sells shares worth $593,997 - Investing.com
Kiniksa Pharmaceuticals CFO sells shares worth $323,008 By Investing.com - Investing.com Canada
Kiniksa Pharmaceuticals CFO sells shares worth $323,008 - Investing.com India
KNSA (Kiniksa Pharmaceuticals International) Treasury Stock : $0.0 Mil (As of Sep. 2024) - GuruFocus.com
Kiniksa Pharmaceuticals officer sells $194k in stock By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals officer sells $194k in stock - Investing.com India
Kiniksa Pharmaceuticals International, plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference - Marketscreener.com
Principal Financial Group Inc. Sells 14,100 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals COO sells shares valued at $357,680 By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals COO sells shares valued at $357,680 - Investing.com India
HHLR Advisors, Ltd. Reduces Stake in Kiniksa Pharmaceuticals Int - GuruFocus.com
Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025? - Insider Monkey
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference 2024 | KNSA Stock News - StockTitan
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference - GlobeNewswire
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
Kiniksa Pharmaceuticals International PLC (KNSA) Trading Down 3. - GuruFocus.com
Kiniksa Pharmaceuticals International, plc Just Missed Earnings With A Surprise LossHere Are Analysts Latest Forecasts - Yahoo Finance
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2024 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earning - GuruFocus.com
Kiniksa Pharmaceuticals International Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Kiniksa Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks
Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings Call Highlights: Impressive ... - Yahoo Finance
Kiniksa Pharm's Revenue Surges 67% in Q3 - The Motley Fool
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Gap Down to $24.04 on Oct 29 - GuruFocus.com
Kiniksa Pharmaceuticals International, plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kiniksa Pharmaceuticals Q3 2024 Earnings: EPS Miss, Revenue Beats Estimates with $112.2 Million - GuruFocus.com
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution - GlobeNewswire
Exploring Kiniksa Pharmaceuticals's Earnings Expectations - Benzinga
What To Expect From Kiniksa Pharmaceuticals International PLC (K - GuruFocus.com
Finanzdaten der Kiniksa Pharmaceuticals International Plc-Aktie (KNSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):